Both Pfizer and Moderna have reported that they should have enough efficacy and safety data to apply for an Emergency Use Authorization by the end of November.
"The flu vaccine efficacy is very dependent on what the strains are circulating at any given time so to hit a 90% in a flu vaccine would be a banner year," said Dr. Susanna Naggie, an associate professor of medicine and vice dean for clinical research at Duke University's School of Medicine.
Some have shown to have a 95% efficacy which, according to Dr. Naggie, is much more than was expected.
Have questions about the COVID-19 vaccine? Send them to us here
Dr. Naggie said the one vaccine that's that effective is the one for Hepatitis B.
"It also means that we're likely to have the early roll out of the vaccine by the end of the year and that's important," Naggie said.
The FDA Vaccine Advisory Committee will have a public hearing and within two to four weeks, the FDA may grant emergency authorization for Pfizer, Moderna or both by the end of December.
Duke Health shares plans for distribution of COVID-19 vaccine available as Pfizer seeks FDA authorization
The initial roll out will only be for high-risk individuals: front-line healthcare workers, first responders and those in long-term care facilities.
Dr. Naggie believes the general public could have access to it by May or June of next year.
"It means we're likely to have an early roll out of a vaccine by the end of the year and that's important."— Josh Chapin (@JoshChapinABC11) November 25, 2020
We got some perspective from our area doctors #vaccines and where all of us stand in getting one.@snaggie1 believes it could happen by next June #ABC11 pic.twitter.com/GN2ZH5uBAp
"That is not a bad place for us to be in at this given time," Naggie said.
Dr. Naggie said she expects the side effects of the COVID-19 vaccine to be similar to that of the shingles vaccine.
FULL CORONAVIRUS COVERAGE
People will react differently to them but "that's actually your body's response and it's a health response."
Raleigh man shares experience as participant in Moderna COVID-19 vaccine trial
Moving forward, Dr. Naggie believes it will be about education.
She said she's been giving and encouraging her patients to get the flu shot for years.
Q&A: Expert explains when the average person may have access to COVID-19 vaccine
"I think also because people hear they are new and novel and that has also led some folks to wonder about the long-term safety," she said. "I hope that we see many of our leaders standing up and supporting vaccination: that for us as a country to restart, get our businesses back, it's going to be critical to have vaccination acceptance across the board."